Indo-Bangla Pharmaceuticals Limited (DSE:IBP)

Bangladesh · Delayed Price · Currency is BDT

14.10

+0.20 (1.44%)

At close: Nov 4, 2026

Market Cap	1.64B +23.7%
Revenue (ttm)	242.10M +165.8%
Net Income	-14.39M
EPS	-0.12
Shares Out	116.21M
PE Ratio	n/a
Forward PE	n/a
Dividend	0.02 (0.11%)
Ex-Dividend Date	Dec 8, 2025

Volume	1,179,519
Open	n/a
Previous Close	13.90
Day's Range	13.90 - 14.30
52-Week Range	10.00 - 21.40
Beta	0.21
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 4, 2026

About DSE:IBP

Indo-Bangla Pharmaceuticals Limited engages in the manufacture and sale of various medicines, medical preparations drugs, and chemicals in Bangladesh and internationally. The company’s principal products include Omeprazole, Esomeprazole, Dexamethasone, Domperidone, Metronidazole, Montelukast, Paracetamol, Sildenafil Citrate, and several other formulations. It markets its products in various forms, such as tablets, capsules. Indo-Bangla Pharmaceuticals Limited was founded in 1954 and is based in Dhaka, Bangladesh. [Read more]

Industry Pharmaceutical Preparations

Founded 1954

Employees 127

Stock Exchange Dhaka Stock Exchange

Ticker Symbol IBP

Full Company Profile

Financial Performance

In fiscal year 2025, DSE:IBP's revenue was 184.18 million, an increase of 4.27% compared to the previous year's 176.64 million. Losses were -36.83 million, -10.12% less than in 2024.

Financial Statements